Drug Price Transparency Act of 2021
Summary
Drug Price Transparency Act of 2021 This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Bill status
in committee
1 of 4 stages cleared
Introduction
Apr 2021
Committee Review
Floor Vote
President
Introduced Apr 29, 2021
Last action Apr 29, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Apr 29, 2021
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
Apr 29, 2021
Introduced
Introduced in Senate
upper
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Mike Braun
RRepublican
Co
Cindy Hyde-Smith
RRepublican
Co
Roger Marshall
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about S 1523
Scope: US
Hi! I can help you understand S 1523. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline